Acarbose ameliorates spontaneous type‑2 diabetes in db/db mice by inhibiting PDX‑1 methylation

Zhou,Diyi; Chen,Lijun; Mou,Xin

doi:10.3892/mmr.2020.11710

Acarbose ameliorates spontaneous type‑2 diabetes in db/db mice by inhibiting PDX‑1 methylation

Authors:
- Diyi Zhou
- Lijun Chen
- Xin Mou
View Affiliations

Affiliations: Department of Endocrinology, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Hangzhou, Zhejiang 310000, P.R. China
Published online on: November 20, 2020 https://doi.org/10.3892/mmr.2020.11710
Article Number: 72
Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic and duodenal homeobox (PDX)‑1 is a gene that plays an important role in pancreatic development and function. Type‑2 diabetes mellitus (T2DM) is a metabolic disease associated with insulin resistance and impaired islet β‑cell function. There is evidence that methylation of PDX‑1 plays a role in the development of T2DM. Acarbose is an α‑glucosidase inhibitor that can effectively delay the absorption of glucose by the body. The aim of the present study was to examine the effect of acarbose on PDX‑1 methylation in islet β‑cells in spontaneous type‑2 diabetic db/db mice. The effect of acarbose on glucose and lipid metabolism in these mice was assessed by measuring food intake, body weight, glycated hemoglobin (HbA1c), glucagon, serum total cholesterol and triglyceride levels, and fasting blood glucose (FBG). Blood glucose levels were also analyzed using intraperitoneal glucose tolerance and insulin tolerance tests. Immunohistochemistry was used to evaluate the effect of acarbose on pathological changes in the pancreas. Moreover, a BrdU assay was used to analyze cell proliferation. Lastly, the effect of acarbose on PDX‑1 methylation was evaluated in mice using methylation‑specific PCR and western blot analysis. In the present study, body weight significantly increased in the acarbose group, compared to the normal group. The levels of HbA1c and glucagon in the T2DM group significantly increased, compared with the normal group, but significantly decreased in acarbose‑treated mice. Moreover, FBG levels significantly decreased in the acarbose groups compared with T2DM mice. Acarbose also promoted cell proliferation, compared with untreated T2DM mice. In addition, PDX‑1 methylation and cytoplasmic expression levels were both downregulated in the acarbose group, compared with the T2DM group. In conclusion, these results suggested that acarbose could promote the proliferation of islet β‑cells and inhibit PDX‑1 methylation in islet β cells from diabetic mice. Thus, acarbose may provide a new strategy to treat T2DM.

View Figures

View References

1	Sharma AK, Bharti S, Goyal S, Arora S, Nepal S, Kishore K, Joshi S, Kumari S and Arya DS: Upregulation of PPARγ by Aegle marmelos ameliorates insulin resistance and β-cell dysfunction in high fat diet fed-streptozotocin induced type 2 diabetic rats. Phytother Res. 25:1457–1465. 2011. View Article : Google Scholar : PubMed/NCBI
2	Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D and Becker DJ: Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh epidemiology of diabetes complications study. Diabetes Care. 26:1374–1379. 2003. View Article : Google Scholar : PubMed/NCBI
3	Regazzi R: MicroRNAs as therapeutic targets for the treatment of diabetes mellitus and its complications. Expert Opin Ther Targets. 22:153–160. 2018. View Article : Google Scholar : PubMed/NCBI
4	Oza MJ and Kulkarni YA: Biochanin A improves insulin sensitivity and controls hyperglycemia in type 2 diabetes. Biomed Pharmacother. 107:1119–1127. 2018. View Article : Google Scholar : PubMed/NCBI
5	Wing RR, Rosen RC, Fava JL, Bahnson J, Brancati F, Gendrano Iii IN, Kitabchi A, Schneider SH and Wadden TA: Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial. J Sex Med. 7:156–165. 2010. View Article : Google Scholar : PubMed/NCBI
6	Zhou Z, Sun B, Li X and Zhu C: DNA methylation landscapes in the pathogenesis of type 2 diabetes mellitus. Nutr Metab (Lond). 15:472018. View Article : Google Scholar : PubMed/NCBI
7	Sharma S and Taliyan R: Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes. Pharmacol Res. 113:320–326. 2016. View Article : Google Scholar : PubMed/NCBI
8	Malipatil N, Lunt M, Narayanan RP, Siddals K, Cortés Moreno GY, Gibson MJ, Gu HF, Heald AH and Donn RP: Assessment of global long interspersed nucleotide element-1 (LINE-1) DNA methylation in a longitudinal cohort of type 2 diabetes mellitus (T2DM) individuals. Int J Clin Pract. e13270Oct 21–2018.(Epub ahead of print). PubMed/NCBI
9	Hudec M, Dankova P, Solc R, Bettazova N and Cerna M: Epigenetic regulation of circadian rhythm and its possible role in diabetes mellitus. Int J Mol Sci. 21:30052020. View Article : Google Scholar
10	Paneni F, Costantino S, Volpe M, Lüscher TF and Cosentino F: Epigenetic signatures and vascular risk in type 2 diabetes: A clinical perspective. Atherosclerosis. 230:191–197. 2013. View Article : Google Scholar : PubMed/NCBI
11	Pedica F, Beccari S, Pedron S, Montagna L, Piccoli P, Doglioni C and Chilosi M: PDX-1 (pancreatic/duodenal homeobox-1 protein 1). Pathologica. 106:315–321. 2014.PubMed/NCBI
12	Zhou G, Yu J, Wang A, Liu SH, Sinnett-Smith J, Wu J, Sanchez R, Nemunaitis J, Ricordi C, Rozengurt E and Brunicardi FC: Metformin restrains pancreatic duodenal homeobox-1 (PDX-1) function by inhibiting ERK signaling in pancreatic ductal adenocarcinoma. Curr Mol Med. 16:83–90. 2016. View Article : Google Scholar : PubMed/NCBI
13	Rafati R, Jalal R, Asoodeh A and Matin MM: Association of rs12255372 (TCF7L2) and D76N (PDX-1) polymorphisms with type 2 diabetes in a population living in Northeast Iran. Arch Iran Med. 18:376–378. 2015.PubMed/NCBI
14	Kaneto H, Matsuoka TA, Kimura T, Obata A, Shimoda M, Kamei S, Mune T and Kaku K: Appropriate therapy for type 2 diabetes mellitus in view of pancreatic β-cell glucose toxicity: ‘The earlier, the better’. J Diabetes. 8:183–189. 2016. View Article : Google Scholar : PubMed/NCBI
15	McIver LA and Tripp J: Acarbose. StatPearls. StatPearls Publishing Copyright © 2020. StatPearls Publishing LLC.; Treasure Island (FL): 2020, simplehttps://www.ncbi.nlm.nih.gov/books/NBK493214Aughust 10–2020
16	Tu J, Liu G, Cao X, Zhu S, Li Q, Ji G, Han Y and Xiao H: Hypoglycemic effects of wheat bran alkyresorcinols in high-fat/high-sucrose diet and low-dose streptozotocin-induced type 2 diabetic male mice and protection of pancreatic β cells. Food Funct. 10:3282–3290. 2019. View Article : Google Scholar : PubMed/NCBI
17	Triplitt C, Cersosimo E and DeFronzo RA: Pioglitazone and alogliptin combination therapy in type 2 diabetes: A pathophysiologically sound treatment. Vasc Health Risk Manag. 6:671–690. 2010.PubMed/NCBI
18	Li FF, Xu XH, Fu LY, Su XF, Wu JD, Lu CF, Ye L and Ma JH: Influence of acarbose on plasma glucose fluctuations in insulin-treated patients with type 2 diabetes: A pilot study. Int J Endocrinol. 2015:9035242015. View Article : Google Scholar : PubMed/NCBI
19	Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA and Butler PC: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes. 52:102–110. 2003. View Article : Google Scholar : PubMed/NCBI
20	Wang X, Zhou L, Li G, Luo T, Gu Y, Qian L, Fu X, Li F, Li J and Luo M: Palmitate activates AMP-activated protein kinase and regulates insulin secretion from beta cells. Biochem Biophys Res Commun. 352:463–468. 2007. View Article : Google Scholar : PubMed/NCBI
21	Shao S, Fang Z, Yu X and Zhang M: Transcription factors involved in glucose-stimulated insulin secretion of pancreatic beta cells. Biochem Biophys Res Commun. 384:401–404. 2009. View Article : Google Scholar : PubMed/NCBI
22	Brissova M, Shiota M, Nicholson WE, Gannon M, Knobel SM, Piston DW, Wright CV and Powers AC: Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J Biol Chem. 277:11225–11232. 2002. View Article : Google Scholar : PubMed/NCBI
23	Kitamura T, Nakae J, Kitamura Y, Kido Y, Biggs WH III, Wright CV, White MF, Arden KC and Accili D: The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic beta cell growth. J Clin Invest. 110:1839–1847. 2002. View Article : Google Scholar : PubMed/NCBI
24	Zhu Y, Liu Q, Zhou Z and Ikeda Y: PDX1, neurogenin-3, and MAFA: Critical transcription regulators for beta cell development and regeneration. Stem Cell Res Ther. 8:2402017. View Article : Google Scholar : PubMed/NCBI
25	Van de Casteele M, Leuckx G, Baeyens L, Cai Y, Yuchi Y, Coppens V, De Groef S, Eriksson M, Svensson C, Ahlgren U, et al: Neurogenin 3+ cells contribute to β-cell neogenesis and proliferation in injured adult mouse pancreas. Cell Death Dis. 4:e5232013. View Article : Google Scholar : PubMed/NCBI